Themis Medicare Limited — Board Meeting, 13-11-2025: Outcome of Board Meeting
13-11-2025 | 01:24 pm
13-11-2025 | 01:24 pm
Themis Medicare's board approved Q2 & H1 results, reporting a consolidated loss of ₹3.62 Cr (Q2) and ₹17.84 Cr (H1). The company also withdrew its merger scheme with Gujarat Themis Biosyn, opting to focus on its core domestic formulations business.
No comments yet. Be the first to comment!
